|
China Shineway Pharmaceutical Group Limited (2877.hk) Valation DCF
CN | Healthcare | Drug Manufacturers - Specialty & Generic | HKSE
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
China Shineway Pharmaceutical Group Limited (2877.HK) Bundle
Améliorez vos choix d'investissement avec la calculatrice DCF de China Shineway Pharmaceutical Group Limited (2877HK)! Utilisez des données financières authentiques, ajustez les projections et dépenses de croissance et observez instantanément comment ces modifications affectent la valeur intrinsèque de l'entreprise.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,889.6 | 2,835.9 | 3,442.2 | 4,218.6 | 4,822.9 | 4,845.1 | 4,867.3 | 4,889.6 | 4,912.1 | 4,934.6 |
| Revenue Growth, % | 0 | -1.86 | 21.38 | 22.56 | 14.32 | 0.45882 | 0.45882 | 0.45882 | 0.45882 | 0.45882 |
| EBITDA | 718.3 | 662.1 | 965.1 | 1,178.4 | 1,516.4 | 1,314.2 | 1,320.2 | 1,326.2 | 1,332.3 | 1,338.4 |
| EBITDA, % | 24.86 | 23.35 | 28.04 | 27.93 | 31.44 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 |
| Depreciation | 218.9 | 222.6 | 194.8 | 198.5 | 189.1 | 287.9 | 289.2 | 290.5 | 291.8 | 293.2 |
| Depreciation, % | 7.58 | 7.85 | 5.66 | 4.7 | 3.92 | 5.94 | 5.94 | 5.94 | 5.94 | 5.94 |
| EBIT | 499.5 | 439.5 | 770.3 | 979.9 | 1,327.3 | 1,026.3 | 1,031.0 | 1,035.7 | 1,040.5 | 1,045.3 |
| EBIT, % | 17.28 | 15.5 | 22.38 | 23.23 | 27.52 | 21.18 | 21.18 | 21.18 | 21.18 | 21.18 |
| Total Cash | 4,238.0 | 4,216.2 | 4,495.7 | 5,392.8 | 6,309.6 | 4,845.1 | 4,867.3 | 4,889.6 | 4,912.1 | 4,934.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | -24.3 | -5.7 | -4.6 | 1,041.2 | 1,307.5 | 490.5 | 492.7 | 495.0 | 497.3 | 499.5 |
| Account Receivables, % | -0.84117 | -0.20014 | -0.13411 | 24.68 | 27.11 | 10.12 | 10.12 | 10.12 | 10.12 | 10.12 |
| Inventories | 460.0 | 473.1 | 627.8 | 702.3 | 958.6 | 846.6 | 850.5 | 854.4 | 858.3 | 862.2 |
| Inventories, % | 15.92 | 16.68 | 18.24 | 16.65 | 19.88 | 17.47 | 17.47 | 17.47 | 17.47 | 17.47 |
| Accounts Payable | 202.3 | 175.5 | 244.1 | 329.7 | 517.7 | 376.3 | 378.0 | 379.7 | 381.5 | 383.2 |
| Accounts Payable, % | 7 | 6.19 | 7.09 | 7.82 | 10.73 | 7.77 | 7.77 | 7.77 | 7.77 | 7.77 |
| Capital Expenditure | -94.4 | -70.5 | -100.0 | -138.2 | -154.1 | -146.6 | -147.3 | -148.0 | -148.6 | -149.3 |
| Capital Expenditure, % | -3.27 | -2.49 | -2.9 | -3.28 | -3.2 | -3.03 | -3.03 | -3.03 | -3.03 | -3.03 |
| Tax Rate, % | 21.83 | 21.83 | 21.83 | 21.83 | 21.83 | 21.83 | 21.83 | 21.83 | 21.83 | 21.83 |
| EBITAT | 391.0 | 328.3 | 595.5 | 772.3 | 1,037.6 | 794.9 | 798.5 | 802.2 | 805.9 | 809.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 282.0 | 421.9 | 603.0 | -202.1 | 737.9 | 1,723.8 | 936.0 | 940.3 | 944.6 | 949.0 |
| WACC, % | 7.71 | 7.7 | 7.71 | 7.71 | 7.71 | 7.71 | 7.71 | 7.71 | 7.71 | 7.71 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 4,516.1 | |||||||||
| Long Term Growth Rate, % | 0.50 | |||||||||
| Free cash flow (T + 1) | 954 | |||||||||
| Terminal Value | 13,227 | |||||||||
| Present Terminal Value | 9,124 | |||||||||
| Enterprise Value | 13,640 | |||||||||
| Net Debt | -5,967 | |||||||||
| Equity Value | 19,606 | |||||||||
| Diluted Shares Outstanding, MM | 755 | |||||||||
| Equity Value Per Share | 25.95 |
What You Will Receive
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled financial data for Shineway Pharmaceutical Group Limited (2877HK).
- Authentic Data: Access to historical performance and future estimations (highlighted in the yellow cells).
- Assumption Flexibility: Adjust forecast parameters such as revenue growth, EBITDA margin, and WACC.
- Instant Calculations: Quickly observe how your inputs influence the valuation of Shineway Pharmaceutical Group Limited (2877HK).
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Layout: Organized for simplicity and accessibility, complete with step-by-step guidance.
Key Features
- Comprehensive DCF Calculator: Features both unlevered and levered DCF valuation models tailored for China Shineway Pharmaceutical Group Limited (2877HK).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital spreadsheet with adjustable inputs specific to the pharmaceutical sector.
- Customizable Forecast Assumptions: Easily adjust growth projections, capital expenditures, and discount rates relevant to (2877HK).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for China Shineway Pharmaceutical Group Limited (2877HK).
- Visual Dashboard and Charts: Graphical representations of key valuation metrics facilitate straightforward analysis.
How It Works
- 1. Access the Template: Download and open the Excel file filled with China Shineway Pharmaceutical Group Limited's (2877HK) preloaded data.
- 2. Update Assumptions: Modify essential inputs such as growth rates, WACC, and capital expenditures.
- 3. Instant Results: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation results.
- 5. Present with Assurance: Deliver professional valuation insights to bolster your decision-making process.
Why Select This Calculator for China Shineway Pharmaceutical Group Limited (2877HK)?
- Time-Saving: Skip the hassle of building a DCF model – it's fully optimized for immediate use.
- Enhanced Accuracy: Dependable financial metrics and formulas help minimize valuation errors.
- Completely Customizable: Adjust the model to align with your unique assumptions and forecasts.
- User-Friendly: Intuitive charts and outputs make the results straightforward to analyze.
- Endorsed by Professionals: Crafted for experts who prioritize both precision and ease of use.
Who Should Utilize This Product?
- Investors: Evaluate China Shineway Pharmaceutical Group Limited’s (2877HK) valuation prior to making stock trades.
- CFOs and Financial Analysts: Optimize valuation procedures and assess financial forecasts for (2877HK).
- Startup Founders: Discover the valuation methodologies applied to major companies like China Shineway Pharmaceutical Group Limited (2877HK).
- Consultants: Provide comprehensive valuation reports for your clients concerning (2877HK).
- Students and Educators: Employ real-time data to practice and instruct on valuation strategies using (2877HK).
Overview of Template Features
- Preloaded 2877HK Data: Historical and forecasted financial information, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-quality spreadsheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for modifying revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financial statements for in-depth analysis.
- Key Ratios: Metrics for profitability, leverage, and efficiency to assess performance.
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.